Energy News / Shareholders Foundation, Inc.

NASDAQ: ESPR Long Term Investor Notice: Investigation of Potential Wrongdoing at Esperion Therapeutics, Inc.

Via: ReleaseWire

Updated 12:00 PM CDT, Mon, October 22,2018

An investigation on behalf of current long term investors in Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares over possible breaches of fiduciary duty by certain officers and directors was announced.

San Diego, CA -- (SBWIRE) -- 10/22/2018 -- An investigation was announced for investors in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) over possible breaches of fiduciary duties by certain directors and officers of Esperion Therapeutics, Inc..

Investors who are current long-term investors in Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: ESPR stocks follows a lawsuit filed recently against Esperion Therapeutics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: ESPR stocks, concerns whether certain Esperion Therapeutics, Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Eastern District of Michigan the plaintiff alleges that between February 22, 2017 and May 1, 2018, the defendants made false and/or misleading statements and/or failed to disclose that Esperion's cholesterol-lowering medication, bempedoic acid, entailed serious undisclosed safety risks, including death, and that as a result of the foregoing, Esperion's public statements were materially false and misleading at all relevant times

On May 2, 2018, Esperion Therapeutics, Inc announced results from its second pivotal Phase 3 study for its cholesterol-lowering medication. Esperion Therapeutics, Inc reported that while the trial met the primary endpoint of safety and tolerability and the key efficacy endpoint, there were 13 deaths in the treatment group compared to only two in the control group.

Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) declined to $33.06 per share on May 3, 2018.

Those who purchased shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaq-espr-long-term-investor-notice-investigation-of-potential-wrongdoing-at-esperion-therapeutics-inc-1069848.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com